tyrosine has been researched along with pnd 1186 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koenig, M; Kwok, C; Liang, C; Lim, ST; McMahon, G; Mielgo, A; Nam, JO; Patel, N; Schlaepfer, DD; Stupack, DG; Sun, C; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C | 1 |
| Kwok, C; Luo, H; McMahon, G; Nam, JO; Patel, N; Phillips, A; Schlaepfer, DD; Stupack, DG; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C | 1 |
2 other study(ies) available for tyrosine and pnd 1186
| Article | Year |
|---|---|
PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphorylation; Signal Transduction; Spheroids, Cellular; src-Family Kinases; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2010 |
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphorylation; Tyrosine; Xenograft Model Antitumor Assays | 2010 |